GH Research to present trial data on October 11, 2026

The meeting schedule includes three posters on October 11 and a company-sponsored symposium on October 10.

Rhea-AI Filing Summary

GH Research PLC (GHRS) will present data from its GH001-TRD-201 and GH001-BD-202 clinical trials at the 39th European College of Neuropsychopharmacology (ECNP) annual meeting, scheduled for October 10–13, 2026, in Munich, Germany. Three posters are scheduled for Poster Session 2 on October 11, 2026, with presentations by Prof. Wiesław J. Cubała, Prof. Bernhard T. Baune, and Dr. Max de Leeuw. The company will sponsor an industry satellite symposium on October 10 titled “Achieving remission in treatment-resistant depression: current evidence and research on rapid-acting antidepressants.”

Key Figures

Clinical-trial posters: 3 posters Annual meeting: 39th annual meeting Poster presentation date: October 11, 2026 +1 more

4 metrics

Clinical-trial posters 3 posters Poster Session 2 on October 11, 2026

Annual meeting 39th annual meeting European College of Neuropsychopharmacology meeting scheduled for October 10–13, 2026

Poster presentation date October 11, 2026 Poster Session 2

Symposium date October 10, 2026 Industry satellite symposium at ECNP

Key Terms

treatment-resistant depression, rapid-acting antidepressants, neuropsychopharmacology, remission

4 terms

treatment-resistant depression medical

"remission in treatment-resistant depression"

A form of major depression that does not improve after a person has tried standard treatments such as common antidepressant medications and therapy; think of it as a stubborn problem that doesn’t respond to the usual fixes. It matters to investors because it represents a large unmet medical need and a higher-risk, higher-reward area for drug developers, with potential for premium pricing, regulatory scrutiny, and durable demand if an effective new therapy is approved.

rapid-acting antidepressants medical

"research on rapid-acting antidepressants"

neuropsychopharmacology medical

"European College of Neuropsychopharmacology annual meeting"

remission medical

"Achieving remission in treatment-resistant depression"

Remission is a medical state where signs and symptoms of a disease have lessened or disappeared, which can be temporary or lasting and may be described as partial or complete. For investors, remission outcomes in clinical trials or patient care signal how well a treatment works and influence a drug’s market potential, future sales, regulatory approval chances and stock valuations — similar to seeing a storm clear and assessing whether the weather will stay fair.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will GHRS present clinical-trial data at ECNP 2026?

GH Research PLC is scheduled to present data from GH001-TRD-201 and GH001-BD-202 in three posters during Poster Session 2 on October 11, 2026.

What is the topic of GHRS’s ECNP 2026 symposium?

The company-sponsored industry satellite symposium is scheduled for October 10, 2026, under the title “Achieving remission in treatment-resistant depression: current evidence and research on rapid-acting antidepressants.”

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/09/2026 - 07:01 AM EDT Accepted by SEC EDGAR 10/09/2026 - 07:00 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026.

Commission File Number: 001-40530

GH Research PLC

(Exact name of registrant as specified in its charter)

Joshua Dawson House

Dawson Street

Dublin 2

D02 RY95

Ireland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒ Form 40-F ☐

GH Research PLC (the “Company”) announces the presentation of data from its GH001-TRD-201 and GH001-BD-202 clinical trials at the 39th European College of Neuropsychopharmacology (ECNP) annual meeting, which is scheduled to take place from October 10-13, 2026, in Munich, Germany. The data will be presented in three posters during Poster Session 2 on October 11, 2026, by Prof. Wiesław J. Cubała, Prof. Bernhard T. Baune, and Dr. Max de Leeuw.

The Company will also sponsor an industry satellite symposium titled “Achieving remission in treatment-resistant depression: current evidence and research on rapid-acting antidepressants” at ECNP on October 10, 2026.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GH Research PLC
Date: October 9, 2026
	By:	/s/ Magnus Halle
	Name:	Magnus Halle
	Title:	Company Secretary

3